At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
Botulinum Toxin Type A 900kDa +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
In Brief
A Phase 4 clinical trial evaluating Botulinum Toxin Type A 900kDa and Botulinum Toxin Type A 150kDa for Blepharospasm. Completed, enrolled 65 participants across 3 sites.
Detailed Summary
This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm. Blepharospasm is characterised by excessive contraction of the muscles around the eye and can lead to repetitive blinking or sustained closure of the eyelids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlepharospasm
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
Primary CompletionJan 2008
First PostedSep 2008
TodayJul 2026
First PostedSep 29, 2008
Enrollment StartJul 1, 2006
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.8 years ago
Interventions
Botulinum Toxin Type A 900kDabiological
6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
Botulinum Toxin Type A 150kDabiological
6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)